Larotrectinib, a highly selective TRK inhibitor, demonstrated rapid and durable responses, high disease control rate, and a favorable safety profile in patients with TRK fusion-positive CNS tumors [28]. The gene discussed is NTRK1; the disease is central nervous system neoplasm.